Target type: biologicalprocess
Any process that generates a purine-containing compound, any nucleobase, nucleoside, nucleotide or nucleic acid that contains a purine base, from derivatives of them without de novo synthesis. [GOC:jl]
Purine salvage pathways are critical for maintaining cellular purine nucleotide pools, which are essential for DNA and RNA synthesis, as well as other crucial cellular processes. These pathways allow cells to recycle pre-existing purine bases, such as adenine, guanine, and hypoxanthine, derived from the breakdown of nucleic acids or dietary sources, rather than synthesizing them de novo. This process saves energy and resources for the cell.
The salvage pathway begins with the uptake of purine bases from the extracellular environment or from the breakdown of cellular components. These bases are then converted into their respective nucleoside monophosphates (NMPs) by specific enzymes.
1. **Adenine** is salvaged by adenine phosphoribosyltransferase (APRT), which catalyzes the reaction of adenine with phosphoribosyl pyrophosphate (PRPP) to form AMP.
2. **Guanine** is salvaged by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), which catalyzes the reaction of guanine with PRPP to form GMP.
3. **Hypoxanthine** is also salvaged by HGPRT, resulting in the formation of inosine monophosphate (IMP), which can be further converted to AMP or GMP.
These NMPs can then be further phosphorylated to nucleoside diphosphates (NDPs) and triphosphates (NTPs), which are the building blocks of DNA and RNA.
The purine salvage pathway plays a crucial role in maintaining cellular homeostasis, ensuring adequate supply of purine nucleotides for various metabolic processes. Defects in these pathways can lead to severe genetic disorders, such as Lesch-Nyhan syndrome, which results from a deficiency in HGPRT activity, causing a buildup of uric acid and neurological abnormalities.'
"
Protein | Definition | Taxonomy |
---|---|---|
Adenosine deaminase | An adenosine deaminase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00813] | Homo sapiens (human) |
Adenosine deaminase | An adenosine deaminase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00813] | Homo sapiens (human) |
Purine nucleoside phosphorylase | A purine nucleoside phosphorylase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00491] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
9-(2-hydroxy-3-nonyl)adenine | 9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase | ||
coformycin | coformycins | EC 3.5.4.4 (adenosine deaminase) inhibitor | |
3-deazaguanine | 3-deazaguanine: structure | ||
adenosine | quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
nebularine | nebularine : A purine ribonucleoside that is 9H-purine attached to a beta-D-ribofuranosyl residue at position 9 via a glycosidic (N-glycosyl) linkage. nebularine: structure | purine ribonucleoside; purines D-ribonucleoside | fungal metabolite |
3-deazaguanosine | 3-deazaguanosine: structure | ||
9-(2-hydroxy-3-nonyl)adenine | (2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. | EHNA | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor |
9-(2-hydroxy-3-nonyl)adenine | (2S,3R)-EHNA : EHNA of absolute configuration 2S,3R. | EHNA | |
1-deazaadenosine | 1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source | ||
pentostatin | pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia. Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | coformycins | antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor |
ag 99 | tyrphostin A46: epidermal growth factor-urogastrone receptor antagonist | ||
8-azanebularine | 8-azanebularine: structure in first source | ||
galidesivir | |||
msh, 4-nle-7-phe-alpha- | polypeptide | dermatologic drug | |
acyclovir | acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections. Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. | 2-aminopurines; oxopurine | antimetabolite; antiviral drug |
guanosine monophosphate | guanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase. Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature. | guanosine 5'-phosphate; purine ribonucleoside 5'-monophosphate | biomarker; Escherichia coli metabolite; metabolite; mouse metabolite |
guanine | 2-aminopurines; oxopurine; purine nucleobase | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | |
guanosine | ribonucleoside : Any nucleoside where the sugar component is D-ribose. | guanosines; purines D-ribonucleoside | fundamental metabolite |
inosine | inosines; purines D-ribonucleoside | Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | |
8-amino-9-(2-thienylmethyl)guanine | |||
allopurinol riboside | allopurinol riboside : A nucleoside analogue that is allopurinol with a beta-D-ribofuranosyl moiety at the 1-position. | nucleoside analogue | metabolite |
8-amino-9-benzylguanine | 8-amino-9-benzylguanine: structure given in first source | ||
forodesine | forodesine: structure in first source | dihydroxypyrrolidine; pyrrolopyrimidine | |
peldesine | peldesine: potent inhibitor of human CCRF-CEM T-cell proliferation; structure given in first source | ||
ci 972 | CI 972: structure given in first source | ||
8-aminoguanine | |||
acyclovir monophosphate | |||
immucillin g | immucillin G: structure in first source | dihydroxypyrrolidine; pyrrolopyrimidine | |
ulodesine | ulodesine: a purine nucleoside phosphorylase inhibitor | ||
8-bromoguanosine | purine nucleoside | ||
9-deaza-9-(3-thienylmethyl)guanine | |||
8-aminoguanosine |